The present invention relates to an erlotinib nanoparticle, a manufacturing method thereof, and a pharmaceutical composition containing the erlotinib nanoparticle, capable of making a patient more conveniently take a medicine by reducing a deviation between moments before and after a meal with an increase in the bioavailability of the medicine. The erlotinib nanoparticle is a solid dispersing body, made by dispersing an erlotinib free base in a diluting agent, and has D90 which is not more than 1000 nm. The diluting agent is selected from among a biocompatible polymer, a surfactant, saccharide, and a combination of the ingredients. The saccharide is selected from among a monosaccharide compound, a disaccharide compound, a polysaccharide compound, sugar-alcohol, and a combination of the ingredients.;COPYRIGHT KIPO 2017
展开▼
